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Abstract 
BACKGROUND: Metabolic syndrome (Met-S) that caused by heredity and Lipoprotein Lipase (LPL). LPL is 
involved in the metabolism of serum lipids. Variations in LPL alter enzyme activity, and the most common 
variations are LPL +495 T > G and LPL Pvu II C > T.  
AIM: This study aimed to identify the role of LPL +495 T > G and LPL PvuII C > T gene variations in subjects with 
Met-S in Javanese ethnic based on age stratification. 
METHODS: We recruited 160 participants of Javanese ethnicity consisting of 80 cases and 80 control subjects. 
Met-S was diagnosed according to the criteria of NCEP ATP III. Peripheral blood samples were collected to 
determine biochemical parameters. Screening for both polymorphisms was made by PCR-RFLP.  
RESULTS: Results found that genotype and allele frequencies for LPL +495 T > G were not significantly different 
between Met-S and controls with and without age stratification. In LPL PvuII C > T based on age stratification, 
there were significant differences between TT vs CC, recessive and dominant models in Met-S and control. In the 
age group > 45 years CC genotypes and TC+CC had increased risk of Met-S compared to TT genotypes. In 
summary, there was no significant association between LPL +495 T > G gene variation with Met-S.  
CONCLUSION: In LPL PvuII gene variation, TC + CC is the risk genotype of Met-S in the age group > 45 years. 
 
 
 
 
 
Introduction 
 
Metabolic syndrome (Met-S) is a common 
metabolic disorder and increases the risk for type 2 
diabetes mellitus, cardiovascular disease and non-
cardiac vascular diseases including stroke, carotid 
artery disease, peripheral artery disease, chronic 
kidney disease, atherosclerotic renal artery stenosis, 
and abdominal aortic aneurysms [1]. The National 
Cholesterol Education Program Adult Treatment 
Panel – III (NCEP ATP-III) guidelines and many 
others have defined Met-S as a combination of three 
or more of the following components: increased waist 
circumference (WC), elevated triglycerides (TG), 
reduced high-density lipoprotein – cholesterol (HDL-
C), elevated blood pressure (BP) and elevated fasting 
plasma glucose (FPG) [2]. 
Heritability can cause Met-S and with 
estimates ranging from 10 to 30% [3]. Lipoprotein 
Lipase (LPL) is involved in the metabolism of lipids. 
Mature LPL is a 448 amino acid glycoprotein with 
chromosomal location 8p22, consisting of 10 exons 
and 9 introns [4]. LPL hydrolyses triglycerides in 
circulation from chylomicrons and very-low-density 
lipoproteins and generates fatty acids for storage in 
the adipose tissue or oxidation in the skeletal muscle 
[5], [6]. Several mutations and variations have been 
described in the LPL gene in humans, most of which 
lead to decreased LPL-activity. Variation in LPL 
altering enzyme activity may confer susceptibility for 
or have a protective effect against triglyceride level 
increase, Met-S and coronary arterial diseases (CAD) 
[7]. 
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Many reports described variations and 
missense mutations in LPL, which are clustered in 
several restriction fragment length polymorphisms 
(RFLPs). An LPL+495 T > G and PvuII C > T are 
common variants of the LPL gene and may be 
associated with subtle alterations in plasma lipids [8]. 
Variation of LPL+495 T > G which results from a 
Thymine (T) to Guanine (G) substitution and PvuII C > 
T which results from a Cytosine (C) to Thymine (T) 
substitution located on intron 6, are located 1.57 kb 
from the Splicing Acceptor (SA) site. This 
polymorphism is the product of a change of cytosine 
for thymine [9]. 
This study aimed to identify the role of LPL 
+495 T > G and LPL PvuII C > T gene variations in 
subjects with Met-S in Javanese ethnic based on age 
stratification. 
 
 
Methods 
 
Design and participants 
This study used a case-control design. Met-S 
and control participants were Javanese ethnics 
matched by gender and age, consisting of 80 cases 
and 80 control subjects (34 males and 46 females, 
respectively), who were recruited from a local regency 
in Yogyakarta, Indonesia. Inclusion criteria for the 
Met-S group were: subjects 20-65 years, diagnosed 
Met-S according to criteria of NCEP ATP III consisting 
of WC ≥ 90 cm for men and ≥ 85 cm for women, BP ≥ 
130 / 85 mmHg or in the treatment, TG level ≥ 150 
mg/dL or in the treatment, HDL-C level < 40 mg/dL for 
men and < 50 mg/dL for women or under treatment 
and FPG ≥ 100 mg/dL or treatment [1], [10]. Inclusion 
criteria for control subject were: 20-65 years and not 
diagnosed with Met-S according to criteria of NCEP 
ATP III. The study was approved by the Medical and 
Health Ethics Committee (MHERC) of the Faculty of 
Medicine, Public Health and Nursing, Universitas 
Gadjah Mada-Dr. Sardjito General Hospital with 
registration number KE/FK/0761/EC/2018. All 
participants in this study signed an inform consent 
form. 
 
Medical history and anthropometry 
 measurements  
Demographic data for all participant included 
age, ethnicity, history of disease, cigarette and alcohol 
consumption. Anthropometry measurements included 
weight (kg), height (cm) and waist circumference (cm). 
Weight was measured using a digital scale by Karada-
Scan (Karada Scan HBF 375, by Omron) in light 
clothing without shoes and socks. Height was 
measured using stadiometers in standing position 
barefoot with feet together and arm by the side. WC 
was measured with tape on the midline between the 
inferior cost of the rib and the superior of the iliac 
crest. BMI was calculated from height and weight 
(kg/m2). 
Blood pressure (mmHg) was measured twice 
by mercury sphygmomanometer in the brachial artery 
above the intercostal fossa after resting for at least 3 
minutes. The mean of the two measurements was 
used for systolic and diastolic blood pressures [11]. 
 
Biochemical measurements 
Biochemical analyses using peripheral blood 
was collected in EDTA blood tubes after 8 hours of 
fasting. FPG concentrations, total cholesterol (TC), 
TG, and HDL-C were measured enzymatically with an 
automated analyser (Cobas c111
R
 analyser with the 
protocol of Glucose HK, HDL cholesterol Gen4, 
Triglycerides, Cholesterol Gen2 from Roche 
diagnostic
R; 
Germany) with standard protocol. 
 
DNA Extraction 
DNA was extracted from buffy coat using the 
FavorPrepᵀᴹ blood genomic DNA extraction mini Kit 
(Favorgen) and stored at -20°C. The concentration of 
DNA extraction used nanodrop to check the 
purification of DNA with the ratio of absorbance at 260 
nm and 280 nm. A ratio of ~ 1.8 is generally accepted 
as “pure” for DNA. 
 
Genotyping and LPL Gene Polymorphism 
 Analysis Digestion  
Genotyping of the LPL +495 T > G and PuvII 
C > T were performed by Polymerase Chain Reaction-
Restriction Fragment Length Polymorphism assays 
(PCR-RFLP). PCR amplification was performed in a 
Thermal Cycler 1000 instrument (Bio-Rad) using 30 
mL of total volume. Amplification follow an initial 
denaturation at 95°C for 7 minutes, followed by 35 
cycles of denaturation at 95°C for 1 minute, annealing 
at 54°C (HindIII) and 58°C (PvuII), respectively for 1 
minute, and extension at 72°C for 1 minute and final 
extension at 72°C for 7 minutes. The primer set is 
shown in Table 1. 
Table 1: Primer set 
Primers 
Enzyme and palindromic 
sequence 
Restriction 
(bp) 
allele 
+495T>G 
F : 5’- 
GATGCTACCTGGATAATCAAAG-3’ 
R : 5’- CAGCTAGACATTGCTAGTGT-3’ 
HindIII 
5’-A”AGCTT-3’ 
5’-TTCGA”A-3’ 
 
138 and 214 
352 
 
T 
G 
Pvu II C>T 
F : 5'- GCTTAATTCTCAATTCAATGTC-
3 
R : 5'- TTTAGACTCTTGTCCAGGT-3 
PvuII 
5’-CAG”CTG-3’ 
5’-GTC”GAC-3’ 
 
188 
150 and 38 
 
C 
T 
 
In LPL +495 T > G, the PCR product was 
digested with HindIII enzyme using 5 U of the enzyme 
at 37°C for 4 hours. In LPL PvuII C > T, using PvuII 
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enzyme 5 U at 38°C for 1 hour. Hind III and Pvu II 
enzyme were purchased from New England BioLabs 
(NEB). 
 
Statistical analysis 
Data analysis was performed for normality 
using Kolmogorov-Smirnov tests. Differences in 
baseline characteristics between Met-S and control 
used independent T-test if data had a normal 
distribution and were expressed as mean ± standard 
deviation and Mann Whitney test if not normally 
distributed with median (min-max) by 95% conﬁdence 
interval (CI). The Hardy – Weinberg equilibrium was 
tested by a goodness-of-fit with the 
2
 test to compare 
the observed genotype frequencies with the expected 
ones among the Met-S subjects. The frequencies of 
the alleles and genotypes among different subgroups 
were compared by the chi-square test. Then, if 
bivariate analysis results were significant, they were 
estimated by adjusted Odds Ratio (OR) and their 95% 
CI from logistic regression analyses with the 
adjustment for BMI and hypercholesterolemia.  
 
 
Results 
 
Baseline characteristics between Met-S and 
control subjects are signiﬁcantly different in Body 
Mass Index (BMI), Waist Circumference (WC), Blood 
Pressure (BP) and metabolic proﬁles (Table 2). The 
total numbers of subjects in this study were 160, 
consisting of 80 patients diagnosed with Met-S (case 
group) and 80 subjects as controls. The selection of 
case and control subjects in this study were matched 
by age and sex. Table 1 shows the WC, BMI, systolic 
and diastolic blood pressure, TG and TC were 
significantly higher in the Met-S group (p < 0.001) as 
compared to controls. 
Table 2: Demographic Characteristics of the Subjects in Met-S 
and control 
Baseline 
characteristic 
Met-S 
(n = 80) 
Control 
(n = 80) 
p 
Aged 44.73 (22.06-63.93) 44.80 (20.46-62.49) 0.883** 
Gender 
Man 
Woman 
 
34 (50) 
46 (50) 
 
34 (50) 
46 (50) 
 
1.000*** 
BMI (kg/m²) 29.97 ± 4.74 24.29 ± 3.62 < 0.001* 
WC (cm) 96.03 ± 10.39 81.71 ± (9.35) < 0.001* 
SBP (mmHg) 
130.00 (100.00-
190.00) 
110.00 (90.00-
155.00) 
< 0.001** 
DBP (mmHg) 85.00 (60.00-145.00) 75.00 (60.00-95.00) < 0.001** 
FPG (mg/dL) 69.20 (44.05-227.60) 69.45 (43.20-171.00) 0.167** 
Triglyceride (mg/dL) 183.72 ± 94.74 101.92 ± 41.09 < 0.001* 
TC (mg/dL) 
182.80 (88.10-
380.20) 
155.15 (95.30-
246.60) 
< 0.001** 
HDL-C (mg/dL) 35.00 (24.40-51.10) 41.90 (22.70-76.70) < 0.001** 
*Independent sample t-test, data presented in the mean (± SD); **Nonparametric using 
Mann-Whitney test, data is presented in median (min-max); ***chi-square test; p value is 
significant < 0.05; BMI = Body Mass Index; DBP = Diastolic blood pressure; FPG = Fasting 
Plasma Glucose; HDL-C = High-Density Lopoprotein Cholesterol; SBP = Systolic blood 
pressure; TC = Total Cholesterol; WC = Waist Circumference. 
 
The LPL +495 T > G genotypes were 
determined by Polymerase Chain Reaction (PCR) and 
digestion using HindIII restriction enzyme (Figure 1). 
 
Figure 1: Results of PCR-RFLP gene variation of LPL + 495T > G; 
M as a marker with 100 bp; lane 1, showed PCR product 352 bp; 
lane 2-7 showed GG genotype with 1 band at 352 bp; Lane 3-4 
showed TG genotypes and consisting of 3 bands each 352 bp, 214 
bp and 138 bp; Lane 5-6 showed TT genotypes with 138 bp and 
214 bp 
 
The LPL PvuII C > T genotypes were 
determined by PCR and digestion using PvuII 
restriction enzyme (Figure 2). 
 
Figure 2: PCR-RFLP results of LPL PvuII C > T gene variation; M 
as a marker with 100 bp; lane 1, showed pPCR product 188 bp; 
lane 2-7 showed CC genotype with 1 band at 188 bp; Lane 4-5 
showed TC genotypes and consisting of 3 bands each 188 bp, 150 
bp and 38 bp; Lane 3-6 showed TT genotypes with 2 bands 150 bp 
and 38 bp. 
 
The population was in Hardy-Weinberg 
Equilibrium (p > 0.05), for LPL +495 T > G and PvuII 
C > T gene variation (Table 3). 
Table 3: Hardy-Weinberg Equilibrium in LPL +495 T > G and 
Pvu II C > T 
Gene variation Observed value Expected value 
2 
(DF) P-value 
LPL +495T > G     
TT 98 101 1.84 0.175 
TG 58 52   
GG 4 7   
PvuIIC > T     
TT 77 76 0.06 0.816 
TC 67 68   
CC 16 15   
DF = 1; 2 = Chi squared test. 
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Genotype and allele frequencies for LPL +495 
T > G were not significantly different between Met-S 
and controls (Table 4). The comparison between the 
additive, recessive and dominant genotype 
frequencies between the Met-S group and the control 
group showed no statistically significant differences. 
Table 4: Genotype and Allele Distribution of LPL + 495T> G 
Genes in Met-S and Control Subjects 
LPL +495 T > G 
Met-S 
N (%) 
Control 
N (%) 
P OR (CI 95%) 
Genotype 
Additive Model 
TT 51 (63.8) 47 (58.8) Ref  
TG 26 (32.5) 32 (40.0) 0.384* 0.749 (0.390-1.437) 
GG 3 (3.8) 1 (1.2) 0.355** 2.765 (0.278-27.51) 
Recessive / Dominant Models 
TT 51 (63.8) 47 (58.8) Ref  
TG+GG 29 (36.2) 33 (41.2) 0.516* 0.810(0.428-1.531) 
GG 3 (3.8) 1 (1.2) Ref  
TG+TT 77 (96.2) 79 (98.8) 0.310** 0.325(0.033-3.192) 
Allele 
T 128 (81.5) 126 (79.2) Ref  
G 29 (18.5) 33 (20.8) 0.609* 0.865(0.496-1.509) 
*Chi-square test; **Fisher exact; significant p value < 0.05; CI: Confidence Interval; OR: 
Odds Ratio; Ref: Reference. 
 
Age stratification in LPL +495 T > G, showed 
no significant differences between genotype additive, 
recessive and dominant models in the Met-S group 
and controls (Table 5).  
Table 5: Age Stratification in the distribution of Genotype and 
Allele in LPL +495 T > G Gene Variations in Age-related Met-S 
LPL +495 T 
> G 
Aged ≤ 45 years Age > 45 years 
Met-S 
n (%) 
Control 
n (%) 
P 
OR (CI, 
95%) 
Met-S 
n (%) 
Control 
n (%) 
P 
OR (CI, 
95%) 
Genotype 
Additive Model 
TT 
27 
(65.9) 
22 
(53.7) 
Ref  
24 
(61.5) 
25 
(64.1) 
Ref  
TG 
11 
(26.8) 
18 
(43.9) 
0.143* 
0.5 
(0.2-1.27) 
15 
(38.5) 
14 
(35.9) 
0.815* 
1.12 
(0.45-2.8) 
GG 
3 
(7.3) 
1 
(2.4) 
0.355** 
2.44 
(0.24-25.1) 
0 0 0 0 
Recessive / Dominant Models 
TT 
27 
(65.9) 
22 
(53.7) 
Ref  
24 
(61.5) 
25 
(64.1) 
Ref  
GG+TG 
14 
(34.1) 
19 
(46.3) 
0.260* 
0.60 
(0.25-1.46) 
15 
(38.5) 
14 
(35.9) 
0.815* 
1.12 
(0.46-2.8) 
GG 
3 
(7.3) 
1 
(2.4) 
Ref  0 0 - - 
TG + TT 
38 
(92.7) 
40 
(97.6) 
0.308** 
0.317 
(0.03-3.18) 
39 
(100) 
39 (100)   
Allele 
T 
65 
(82.3) 
62 
(76.5) 
Ref  
63 
(80.8) 
64 
(82.1) 
Ref  
G 
14 
(17.7) 
19 
(23.5) 
0.370* 
0.703 
(0.32-1.52) 
15 
(19.2) 
14 
(17.9) 
0.837* 
1.09 
(0.49-2.40) 
*Chi-square test; **Fisher exact; significant p value < 0.05; CI: Confidence Interval; OR: 
Odds Ratio; Ref: Reference. 
 
In the ≤ 45 years age group, the distribution of 
TT genotypes was a greater compared to TG and GG 
genotypes frequency in the Met-S group although not 
statistically significantly different. Comparison of 
dominant and recessive models also found no 
statistically significant differences between the Met-S 
and control group. In group > 45 years, no GG 
genotypes were found in either Met-S or control 
subjects. Also, the distribution of genotypes and 
alleles of LPL + 495T > G gene variation with Met-S in 
subjects aged > 45 years there had no statistically 
significant differences. 
Genotype and allele frequencies for LPL PvuII 
C > T were not significantly different between Met-S 
and controls (Table 6). The most frequent genotype 
was TT in both study populations, with 38% in the 
Met-S group and 39% in controls. In LPL PvuII C > T, 
the genotype TC had the most frequent in the Met-S 
group compared to controls but it was not significantly 
different. 
Table 6: Genotype and Allele Distribution of LPL PvuII C>T 
Genes in Met-S and Control Subjects 
LPL PvuII C>T 
Met-S 
n (%) 
Control 
n (%) 
P OR (CI, 95%) 
Genotype  
Additive Model 
TT 38 (47.5) 39 (48.8) Ref  
TC 34 (42.5) 33 (41.2) 0.867* 1.057 (0.549-2.036) 
CC 8 (10.0) 8 (10.0) 0.962* 1.026 (0.350-3.013) 
Recessive/Dominant Models 
TT 38 (47.5) 39 (48.8) Ref  
TC+CC 42 (52.5) 41 (51.2) 0.874* 1.051 (0.565-1.955) 
CC 8 (10.0) 8 (10.0) Ref  
TC+TT 72 (90.0) 71 (90.0) 1.000* 1.000 (0.356-2.809) 
Allele 
T 110 (72.4) 111 (73.0) Ref  
C 42 (27.6) 41 (27.0) 0.898* 1.034 (0.624-1.712) 
*Chi-square test; **Fisher exact; significant p value < 0.05; CI: Confidence Interval; OR: 
Odds Ratio; Ref: Reference. 
 
Age stratification in LPL PvuII C > T (Table 7) 
showed there were significant differences between TT 
vs CC, recessive and dominant models in Met-S and 
control. The distribution of TT genotypes and T on 
LPL PvuII > T gene variations age group ≤ 45 years 
had a greater frequency in the Met-S group compared 
to TC and CC genotypes although no statistically 
significant differences were found. In the age group > 
45 years, the distribution of TC genotypes in LPL PvuI 
C > T gene variation was higher in the Met-S group 
compared to TT and CC genotypes. CC genotypes 
and TC + CC had increased risk of Met-S compared 
to TT genotypes. 
Table 7: Age Stratification in the distribution of Genotype and 
Allele in LPL PvuII C > T Gene Variations in Age-related Met-S 
LPL PvuII 
C > T 
Aged ≤ 45 years Age > 45 years 
Met-S 
n (%) 
Control 
n (%) 
P 
OR (CI, 
95%) 
Met-S 
n (%) 
Control 
n (%) 
P 
OR (CI, 
95%) 
Genotype 
Additive Model 
TT 
24 
(58.5) 
16 
(39.0) 
Ref 1.00 
14 
(35.9) 
23 
(59.0) 
Ref 1.00 
TC 
14 
(34.1) 
17 
(41.5) 
0.214* 
0.55 
(0.21- 
1.42) 
20 
(51.3) 
16 
(41.0) 
0.129* 
2.054 
(0.81-5.23) 
CC 
3 
(7.3) 
8 
(19.5) 
0.054* 
0.25 
(0.06-
1.09) 
5 
(12.8) 
0 0.032
#
 17.83 
Recessive/Dominant Models 
TT 
24 
(58.5) 
16 
(39.0) 
Ref 
 
  
 
 14 
 (35.9) 
23 
(59.0) 
Ref  
TC + 
CC 
17 
(41.5) 
25 
(61.0) 
0.077* 
0.453 
(0.19-1.1) 
25 
(64.1) 
16 
(41.0) 
0.070
#
 
2.567 
(1.03-6.40) 
CC 
3 
(7.3) 
8 
(19.5) 
 
Ref 
 
 
 
5 
(12.8) 
0 Ref  
TC + 
TT 
38 
(92.7) 
33 
(80.5) 
0.105* 
3.07 
(0.75-
12.5) 
34 
(87.2) 
39 (100) 0.064
#
 0.079 
Allele 
T 
62 
(78.5) 
49 
(66.2) 
Ref 1.00 
48 
(65.8) 
62 
(79.5) 
Ref 1.00 
C 
17 
(21.5) 
25 
(33.8) 
0.089* 
0.54 
(0.26-
1.11) 
25 
(34.2) 
16 
(20.5) 
0.058* 
2.02 
(0.97-4.2) 
*Chi-square test; **Fisher exact; significant p value < 0.05; CI: Confidence Interval; OR: 
Odds Ratio; Ref: Reference. 
 
In the age group > 45 years, multivariate 
analysis showed a value of p > 0.05 in the Hosmer 
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and Lemeshow test (Table 8). Simultaneously, obesity 
and genetic variation could contribute to causing Met-
S as much as 41.6%. Obese patients had 13.55 times 
increase risk of Met-S compare to the non-obese 
subject and the result was statistically significant. 
Subjects with TC + CC genotypes had 3.62 times 
higher risk of Met-S compared to TT genotype. 
Table 8: Multivariate logistic regression analysis of the 
relationship between Pvu II C > T gene variation and Met-S at 
age > 45 years 
Variable B SE P Adjusted OR (95%, CI) 
Obesity 2.606 0.590 < 0.001 
13.55 
(4.27-43.03) 
Genotype     
TT Ref    
TC + CC 1.287 0.588 0.029 
3.62 
(1.14-11.48) 
 
 
Discussion 
 
A study of the relationship gene variation in 
the LPL shown different result and the regulation of 
lipid concentration is complex [12]. Met-S is 
associated with genetics and can be influenced by the 
environment. Several genetic studies show different 
results, and this is likely because Met-S is not only 
caused by one type of gene but is also caused by the 
interaction of several genes and is influenced by 
environmental factors. Also, population genetic 
studies shown ethnic differences are one of the 
factors that influence differences in genotype 
frequency found in both LPL + 495T > G and PvuII > T 
gene variations. For example, food intake that may be 
very different between ethnic groups modulates the 
genetic influence on lipid metabolism [13]. Variations 
of the LPL + 495T > G and PvuII C > T, which are 
located respectively in introns 8 and intron 6, have 
host elements that regulate gene transcription and 
translation [14]. Although introns do not encode amino 
acids, they play an important role in processing mRNA 
precursors and the incorporation of exons as protein-
coding [12]. 
 LPL +495 T > G gene variation, and the 
frequency of TT genotypes in some countries are 
more prevalent in most case groups compared to 
control groups such as Egypt (45%) [15], Saudi Arabia 
(50.8%) [8], Iran (58.8%) [16],
 
India (48.5%) [17], Iran 
(56, 5%) [18] and in this study (63.8%). In this study, 
TT frequencies were more common in controls 
compared to cases. Lipoprotein Lipase Pvu II C > T 
gene variation in this research was the same as 
research conducted in the populations in Turkey, 
Saudi Arabia, Korea and Egypt [6], [8], [19], [20]. [19]. 
also reported that TC genotypes had a higher 
frequency in patients with coronary artery disease 
compared to the control group. 
 In the age group > 45 years, in the 
dominant model, TC + CC genotypes can increase the 
risk of Met-S by 2.567 (95% CI: 1.03-6.40). After 
multivariate analysis, it was found that TC + CC 
genotypes increased the risk of Met-S by 3.62 times 
compared to TT genotypes. A similar study was done 
by Pereira et al., in stroke patients in Colombia with a 
median age of 64 years without analysing food intake 
data and physical activity found that TT genotypes 
and T alleles were protective factors for stroke events 
[14]. This is different from the research conducted by 
Shin et al. which found no association between food 
intake and physical activity with variations in the LPL 
PvuII C > T gene in the population in Korea. In the 
study, TT genotypes showed an increase in 
triglyceride levels and a decrease in HDL and TT + TC 
genotypes with 1.5 times increased risk of Met-S 
compared to CC genotypes. Decreased LPL due to 
gene variation causes inhibition of lipolysis. Inhibition 
of lipolysis causes increases in VLDL and 
chylomicron. Furthermore, the degradation of 
triglycerides in adipose tissue results in an increase in 
free fatty acids in the blood. Increased triglycerides 
are caused by a decrease in the utilisation of lipids by 
tissue and then can cause Met-S [6]. The differences 
in this research with previous studies include the lack 
of a large number of samples, ethnic differences and 
several environmental factors such as physical activity 
and food intake that are not controlled for the research 
subjects. The number of samples used in the study 
will affect the strength of the statistical results so that 
the study of the relationship of gene variation to an 
illness requires a greater number of samples. Also, 
more control is needed on environmental factors that 
can affect the results. 
There was no association between LPL +495 
T > G gene variation with Met-S. In LPL PvuII gene 
variation, TC + CC is the risk genotype of Met-S in the 
age group > 45 years but no significantly different in 
the age group ≤ 45 years. 
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